Zynerba Pharmaceuticals (ZYNE)

[Leonard McKinley]

In my opinion, the stock should have gone to $17 or more on the report of these results because the results proved that the transdermal delivery system is safe and effective. Given the already proven "approvability" by the FDA of medical CBD use (GWPH), plus the superiority of medicinal grade, pure, synthetic Zyne CBD, plus the improved safety profile of transdermal delivery, …. the probability of Zyne's DEE product being approved and commercialized has increased very substantially. Furthermore, the probability of all of the other targeted Zyne indications has also improved considerably. The stock should reasonably have gone to $17 or even $20, and certainly will, once this insane confusion is put behind us.
The company will present next Tuesday at Laudenburg, Thalman and I expect that all of this silly discussion of AE's and SAE's will be fully clarified to the satisfaction of even the most moronic short seller.
BUY, BUY, BUY!